A new Inserm Transfert Technology Offers experience coming soon in May!

BIO13363-T1

PPAR-gamma agonist as target for the treatment of Rapidly Progressive GlomeruloNephritis

This study demonstrates the pivotal role of the local PPAR-gamma agonist system in maintaining podocyte quiescence and orchestrating the global glomerular tolerance to a severe immune-complex-mediated disease. PPAR-gamma agonist was found to be a downstream effector of the NRF2 pathway, unveiling the critical protective role of both NRF2 activity and PPAR-gamma. We also provide proof of principle that delayed PPAR-gamma agonism could display therapeutic action on glomerular function and structure in a severe model of Rapidly Progressive GlomeruloNephritis. (J Am Soc Nephrol. 2016 Jan;27(1):172-88. doi: 10.1681/ASN.2014111080. Epub 2015 May 21.)


Keywords : Rapidly Progressive GlomeruloNephritis
Patent Application number : PCT/FR2014/052802
Patent Application date : 2014-11-04
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : -
Rare disease : Yes
Second indication : Yes
Inventors : Carole HENIQUE-GRECIET
Pierre-Louis THARAUX
Guillaume BOLLÉE
Publications :
  • J Am Soc Nephrol. 2016 Jan;27(1):172-88. doi: 10.1681/ASN.2014111080. Epub 2015 May 21.

Related offers


The 10 Last viewed

You haven't seen any form yet.